29.52
price down icon6.58%   -2.08
after-market After Hours: 29.50 -0.02 -0.07%
loading
Avidity Biosciences Inc stock is traded at $29.52, with a volume of 3.28M. It is down -6.58% in the last 24 hours and down -3.66% over the past month.
See More
Previous Close:
$31.60
Open:
$30.1
24h Volume:
3.28M
Relative Volume:
2.52
Market Cap:
$4.00B
Revenue:
$10.12M
Net Income/Loss:
$-280.49M
P/E Ratio:
-10.21
EPS:
-2.89
Net Cash Flow:
$-188.51M
1W Performance:
-11.35%
1M Performance:
-3.66%
6M Performance:
-35.73%
1Y Performance:
+15.67%
1-Day Range:
Value
$28.59
$30.25
1-Week Range:
Value
$28.59
$33.28
52-Week Range:
Value
$21.56
$56.00

Avidity Biosciences Inc Stock (RNA) Company Profile

Name
Name
Avidity Biosciences Inc
Name
Phone
858-401-7900
Name
Address
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
2024-12-07
Name
Latest SEC Filings
Name
RNA's Discussions on Twitter

Compare RNA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
RNA
Avidity Biosciences Inc
29.52 4.00B 10.12M -280.49M -188.51M -2.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-13-25 Initiated Citigroup Buy
Mar-12-25 Initiated BMO Capital Markets Outperform
Mar-07-25 Initiated Scotiabank Sector Outperform
Dec-20-24 Initiated H.C. Wainwright Buy
Nov-26-24 Initiated RBC Capital Mkts Outperform
Sep-24-24 Initiated Goldman Buy
Aug-28-24 Initiated Barclays Overweight
May-03-24 Initiated BofA Securities Buy
Mar-14-24 Initiated Cantor Fitzgerald Overweight
May-22-23 Upgrade Evercore ISI In-line → Outperform
Mar-31-23 Downgrade Evercore ISI Outperform → In-line
Jul-20-22 Initiated Chardan Capital Markets Buy
Jul-12-22 Initiated Raymond James Strong Buy
Sep-07-21 Initiated Evercore ISI Outperform
Jun-17-21 Initiated Needham Buy
Apr-26-21 Resumed Credit Suisse Outperform
Jul-07-20 Initiated Cowen Outperform
Jul-07-20 Initiated Credit Suisse Outperform
Jul-07-20 Initiated SVB Leerink Outperform
Jul-07-20 Initiated Wells Fargo Overweight
View All

Avidity Biosciences Inc Stock (RNA) Latest News

pulisher
10:56 AM

Avidity Completes Enrollment in Del-brax Trial's Biomarker Group for Facioscapulohumeral Muscular Dystrophy - MarketScreener

10:56 AM
pulisher
10:49 AM

Avidity Biosciences’s SWOT analysis: stock poised for growth amid clinical progress - Investing.com

10:49 AM
pulisher
09:00 AM

Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy - PR Newswire

09:00 AM
pulisher
08:38 AM

Cantor Fitzgerald maintains $96 target on Avidity Biosciences stock - Investing.com India

08:38 AM
pulisher
Mar 26, 2025

The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (NASDAQ:RNA) - Seeking Alpha

Mar 26, 2025
pulisher
Mar 22, 2025

Avidity Biosciences chief scientific officer sells $365,867 in stock By Investing.com - Investing.com Australia

Mar 22, 2025
pulisher
Mar 22, 2025

Avidity Biosciences CFO Michael MacLean sells $246,424 in stock By Investing.com - Investing.com Australia

Mar 22, 2025
pulisher
Mar 22, 2025

Avidity Biosciences Inc Stock: Leadership Sells Shares Amid Clinical Success - Sharewise

Mar 22, 2025
pulisher
Mar 21, 2025

Avidity Biosciences chief HR officer sells $241,583 in stock By Investing.com - Investing.com Australia

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences CFO Michael MacLean sells $246,424 in stock - Investing.com India

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences CEO Sarah Boyce sells $979,563 in stock - Investing.com India

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences CEO Sarah Boyce sells $979,563 in stock By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences chief scientific officer sells $365,867 in stock - Investing.com

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences chief medical officer sells $297,490 in stock - Investing.com

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences Executives Sell Shares for Tax Obligations - TradingView

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences chief HR officer sells $241,583 in stock - Investing.com

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences announces inducement grants under Nasdaq listing rule 5635(C)(4) - Marketscreener.com

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nasdaq

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences Signals Growth: Awards 152K Shares to 16 New Hires - Stock Titan

Mar 21, 2025
pulisher
Mar 19, 2025

H.C. Wainwright maintains $72 target on Avidity Biosciences stock By Investing.com - Investing.com Canada

Mar 19, 2025
pulisher
Mar 18, 2025

Forecasting The Future: 13 Analyst Projections For Avidity Biosciences - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

Avidity’s del-zota elicits 25% increase in dystrophin in DMD patients - Yahoo

Mar 18, 2025
pulisher
Mar 18, 2025

New Duchenne Results Put Avidity On Course For Filing - insights.citeline.com

Mar 18, 2025
pulisher
Mar 18, 2025

Avidity Biosciences reports progress in DMD treatment trial By Investing.com - Investing.com Australia

Mar 18, 2025
pulisher
Mar 18, 2025

Citi maintains $70 target on Avidity Biosciences stock post-trial By Investing.com - Investing.com Canada

Mar 18, 2025
pulisher
Mar 17, 2025

Avidity eyes 2025 BLA on back of positive DMD data - BioWorld Online

Mar 17, 2025
pulisher
Mar 17, 2025

Avidity Biosciences Touts Positive Data From Early-Stage Duchenne Muscular Dystrophy Study Data, FDA Submission Expected By End Of 2025 - Benzinga India

Mar 17, 2025
pulisher
Mar 17, 2025

Avidity Biosciences Shares Tumble Despite Trial Success - TipRanks

Mar 17, 2025
pulisher
Mar 17, 2025

Avidity Biosciences reports progress in DMD treatment trial - Investing.com India

Mar 17, 2025
pulisher
Mar 17, 2025

Avidity Biosciences Announces Positive EXPLORE44 Trial Results - TipRanks

Mar 17, 2025
pulisher
Mar 17, 2025

Avidity Biosciences Announces Positive Topline Del-Zota Data In DMD44 Trial -March 17, 2025 at 07:12 am EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skip - Financial Times

Mar 17, 2025
pulisher
Mar 14, 2025

Bank of New York Mellon Corp Buys 59,295 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - Defense World

Mar 14, 2025
pulisher
Mar 14, 2025

BMO Capital Markets Begins Coverage on Avidity Biosciences (NASDAQ:RNA) - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Citigroup Initiates Coverage of Avidity Biosciences (RNA) with Buy Recommendation - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - The Malaysian Reserve

Mar 13, 2025
pulisher
Mar 13, 2025

Avidity Biosciences Stock Climbs Amid Promising Prospects - TipRanks

Mar 13, 2025
pulisher
Mar 13, 2025

Avidity Biosciences’s SWOT analysis: RNA therapy pioneer’s stock poised for growth By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 13, 2025

BMO Capital Initiates Coverage of Avidity Biosciences (RNA) with Outperform Recommendation - MSN

Mar 13, 2025
pulisher
Mar 12, 2025

Avidity Biosciences chief scientific officer sells $602,614 in stock By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 12, 2025

Avidity Biosciences Announces Upcoming Presentations at the Musc - GuruFocus.com

Mar 12, 2025
pulisher
Mar 12, 2025

Avidity Biosciences chief scientific officer sells $602,614 in stock - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference – Company AnnouncementFT.com - Financial Times

Mar 12, 2025
pulisher
Mar 12, 2025

Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks - Benzinga India

Mar 12, 2025
pulisher
Mar 12, 2025

This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Mar 12, 2025
pulisher
Mar 12, 2025

Avidity Biosciences to Participate in Upcoming Investor Conferen - GuruFocus.com

Mar 12, 2025
pulisher
Mar 12, 2025

BMO starts coverage on Avidity with 'outperform', says first-in-disease therapies in sight - TradingView

Mar 12, 2025
pulisher
Mar 12, 2025

BMO Capital Initiates Avidity Biosciences at Outperform With $72 Price Target -March 12, 2025 at 07:10 am EDT - MarketScreener

Mar 12, 2025
pulisher
Mar 12, 2025

Avidity Biosciences’s SWOT analysis: RNA therapy pioneer’s stock poised for growth - Investing.com India

Mar 12, 2025
pulisher
Mar 11, 2025

BMO CAPITAL INITIATES AVIDITY BIOSCIENCES WITH OUTPERFORM RATING By Investing.com - Investing.com UK

Mar 11, 2025
pulisher
Mar 11, 2025

Avidity Biosciences (NASDAQ:RNA) Price Target Cut to $48.00 by Analysts at Bank of America - Defense World

Mar 11, 2025

Avidity Biosciences Inc Stock (RNA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Cap:     |  Volume (24h):